VLS-1272

CAT: 0804-HY-153066-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-153066-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
VLS-1272 (Compound 22) is an orally active KIF18A inhibitor that binds to the KIF18A-microtubule complex in an ATP-noncompetitive manner (IC50 = 41 nM), blocking its ATPase activity and inhibiting microtubule translocation. This leads to abnormal accumulation of KIF18A at spindle poles, disrupting chromosome alignment and inducing mitotic arrest and apoptosis in CINHigh tumor cells (e.g., ovarian cancer OVCAR-3, breast cancer JIMT-1) . VLS-1272 is a promising candidate for anti-tumor research[1][2].
CAS Number
[2914878-00-3]
Product Name Alternative
KIF18A-IN-7
UNSPSC
12352005
Target
Apoptosis; Kinesin; Microtubule/Tubulin
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/kif18a-in-7.html
Concentration
10mM
Purity
99.63
Solubility
DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=S(C1=CC(C(N2CC3(CCC4(CC4)CC3)C5=CC(NS(C)(=O)=O)=CC=C52)=O)=CC=C1)(NC(C)(C)C)=O
Molecular Formula
C27H35N3O5S2
Molecular Weight
545.71
References & Citations
[1]COGAN, et al. SPIRO INDOLINE INHIBITORS OF KIF18A. Patent WO2023028564.|[2]Phillips AF, et al. Targeting chromosomally unstable tumors with a selective KIF18A inhibitor. Nat Commun. 2025 Jan 2;16 (1) :307.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Popular Products